You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches

61 search results for: biologics

ERS 2024 | Targeting IL-33 in COPD: Exploring New Frontiers for COPD Management
expert video

ERS 2024 | Targeting IL-33 in COPD: Exploring New Frontiers for COPD Management

Pulmonology
Professors Klaus Rabe, Paola Rogliani, and Dr. Stephanie Christenson explore the complexity of inflammatory pathways and phenotypes in COPD. They provide insights into the genetic association of IL-33 with COPD, discuss preclinical findings, and review ongoing clinical research targeting IL-33 in COPD.
View more
ERS 2024 | IL-33 A Promising Target
expert video

ERS 2024 | IL-33 A Promising Target

Pulmonology
Professor Klaus Rabe presents the latest clinical data on current and emerging biologic therapies targeting IL-33 in COPD.
View more
EAACI 2023 | What is New in the Treatment of Children
expert video

EAACI 2023 | What is New in the Treatment of Children

Dermatology
Clinical trial and real-world data for targeted therapies for children with atopic dermatitis – Presentation from the ADVENT symposium at EAACI 2023.
View more
Targeting Type 2 Inflammation in Children with Atopic Dermatitis: Opportunity for Early Intervention? - Q&As
expert video

Targeting Type 2 Inflammation in Children with Atopic Dermatitis: Opportunity for Early Intervention? - Q&As

Dermatology
Clinical trial and real-world data for targeted therapies for children with atopic dermatitis– Presentation from the ADVENT symposium at EAACI 2023.
View more
Targeting Type 2 Inflammation in Children with AD​
expert video

Targeting Type 2 Inflammation in Children with AD​

Dermatology
The impact of type 2 inflammation in itch and barrier dysfunction in atopic dermatitis – Presentation from the ADVENT symposium at EAACI 2023.
View more
Targeting Type 2 Inflammation in Children with Atopic Dermatitis: Opportunity for Early Intervention?
expert video

Targeting Type 2 Inflammation in Children with Atopic Dermatitis: Opportunity for Early Intervention?

Dermatology
Presentations from the ADVENT symposium at the EAACI 2023 congress on targeting type 2 Inflammation in children with atopic dermatitis.
View more
The Disease Burden of AD in Children and the Impact of Type 2 Comorbidities 
expert video

The Disease Burden of AD in Children and the Impact of Type 2 Comorbidities 

Dermatology
Multidimensional disease burden of atopic dermatitis in children from a real-world case study – Presentation from the ADVENT symposium at EAACI 2023.
View more
CÓMO AFECTA LA DERMATÍTIS ATÓPICA EN LAS ACTIVIDADES DIARIAS Y LAS EMOCIONES DE LOS PACIENTES Y SUS FAMILIAS
expert video

CÓMO AFECTA LA DERMATÍTIS ATÓPICA EN LAS ACTIVIDADES DIARIAS Y LAS EMOCIONES DE LOS PACIENTES Y SUS FAMILIAS

Dermatology
Debate sobre el impacto de la DA en la vida afectiva del paciente, el entorno escolar y laboral así como en todas sus actividades diarias.
View more
CONCLUSIONES Y PREGUNTAS
expert video

CONCLUSIONES Y PREGUNTAS

Dermatology
Conclusiones y preguntas de la audiencia sobre la sesión del impacto de la DA en la salud mental del paciente y familiares.
View more
La DA en pacientes pediátricos: Novedades en el abordaje terapéutico de la Dermatitis Atópica en niños a partir de 6 meses de edad
expert video

La DA en pacientes pediátricos: Novedades en el abordaje terapéutico de la Dermatitis Atópica en niños a partir de 6 meses de edad

Dermatology
En esta tercera escala de ADVENT ON TOUR en MADRID contamos con la Dra. Lucero Noguera, dermatóloga en el Hospital Infantil Universitario Niño Jesús nos presenta las novedades en el abordaje terapéutico de la dermatitis atópica pediátrica.
View more
La DA en pacientes pediátricos: Experiencia con Dupilumab
expert video

La DA en pacientes pediátricos: Experiencia con Dupilumab

Dermatology
En esta tercera escala de ADVENT ON TOUR en MADRID contamos con la Dra. Marta Feito, dermatóloga en el Hospital Universitario La Paz, presentó su experiencia con Dupilumab.
View more
From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP
expert video

From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

Rhinology
Prof. Peter Hellings discusses the interconnection between the pathophysiology, burden and clinical management of uncontrolled and/or severe CRSwNP.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: SpainChange country/region